NZ630795A - Crystalline form of vsn16 - Google Patents

Crystalline form of vsn16

Info

Publication number
NZ630795A
NZ630795A NZ630795A NZ63079514A NZ630795A NZ 630795 A NZ630795 A NZ 630795A NZ 630795 A NZ630795 A NZ 630795A NZ 63079514 A NZ63079514 A NZ 63079514A NZ 630795 A NZ630795 A NZ 630795A
Authority
NZ
New Zealand
Prior art keywords
crystalline form
disclosed
vsn16
compound
free base
Prior art date
Application number
NZ630795A
Other languages
English (en)
Inventor
David Selwood
Original Assignee
Canbex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbex Therapeutics Ltd filed Critical Canbex Therapeutics Ltd
Publication of NZ630795A publication Critical patent/NZ630795A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ630795A 2013-01-18 2014-01-17 Crystalline form of vsn16 NZ630795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300903.0A GB201300903D0 (en) 2013-01-18 2013-01-18 Crystalline Form
PCT/GB2014/050127 WO2014111720A1 (en) 2013-01-18 2014-01-17 Crystalline form of vsn16

Publications (1)

Publication Number Publication Date
NZ630795A true NZ630795A (en) 2016-07-29

Family

ID=47843537

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630795A NZ630795A (en) 2013-01-18 2014-01-17 Crystalline form of vsn16

Country Status (9)

Country Link
US (1) US9682924B2 (https=)
EP (1) EP2945619B1 (https=)
JP (1) JP2016505036A (https=)
CN (1) CN105142626A (https=)
CA (1) CA2897524A1 (https=)
GB (1) GB201300903D0 (https=)
NZ (1) NZ630795A (https=)
RU (1) RU2015134560A (https=)
WO (1) WO2014111720A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256112A1 (en) * 2015-02-13 2017-12-20 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403864D0 (en) * 2004-02-20 2004-03-24 Ucl Ventures Modulator
GB0903956D0 (en) 2009-03-06 2009-04-22 Ucl Business Plc Process

Also Published As

Publication number Publication date
WO2014111720A1 (en) 2014-07-24
GB201300903D0 (en) 2013-03-06
EP2945619B1 (en) 2019-05-08
RU2015134560A (ru) 2017-02-28
US20150353476A1 (en) 2015-12-10
US9682924B2 (en) 2017-06-20
CA2897524A1 (en) 2014-07-24
CN105142626A (zh) 2015-12-09
EP2945619A1 (en) 2015-11-25
JP2016505036A (ja) 2016-02-18

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EP4643945A8 (en) Neuroactive steroids and methods of use thereof
WO2016044641A3 (en) Carm1 inhibitors and uses thereof
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
IN2014MN02106A (https=)
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
IN2013MU02828A (https=)
PH12018500378B1 (en) Novel annelated phenoxyacetamides
MX390763B (es) Compuestos de tetraciclina
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2018015990A (es) Compuestos terapeuticos.
PH12015501056A1 (en) 2-pyridone compound
NZ630795A (en) Crystalline form of vsn16
WO2015102017A8 (en) Processes for the preparation of lorcaserin
WO2016022700A3 (en) Tlr-independent small molecule adjuvants
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
PH12015501696B1 (en) Prophylactic or therapeutic drug for constipation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2019 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20180112

LAPS Patent lapsed